Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- September15 2003
- Volume 10
- Issue 17
Up & Running
Advertisement
Fortune
A key to investment success is togravitate toward companieswith robust growth stories. Accordingto , the followingare the top 10 fastest-growingcompanies for 2003:
- InVision Technologies
- American Home Mortgage Holdings
- AdvancePCS
- Career Education
- American Healthways
- Corinthian Colleges
- New York Community Bancorp
- eBay
- Dynacq International
- EDO
Note:
Never invest in a stockwithout first fully researching it.
Articles in this issue
about 18 years ago
Are You Partners in Life & Liability?about 18 years ago
Make the Best Use of Frequent-Flier Milesabout 18 years ago
Cardiac Care Found to Be Lackingabout 18 years ago
Who Owns the Building?about 18 years ago
Learn the Art of Dealership Negotiationabout 18 years ago
Pioneer Woman Physician and Educatorabout 18 years ago
African-American Doctor's Vital Legacyabout 18 years ago
Does the Market Offer Any Safe Stocks?about 18 years ago
Clear the Stock Market Clouds from Viewabout 18 years ago
Blackout Reveals a US Market in ControlAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5